NCT01511562 · OUTCOME

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma · Source last updated 2026-01-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 7 years

What was measured

Number of patients reporting at least one adverse event at least possibly related to treatment.

Groups in this outcome

Arm I

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant. \> \> carmustine: Given IV \> \> thiotepa: Given IV \> \> stem cell transplant \> \> G-CSF

Arm II

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy. \> \> cytarabine: Given IV \> \> etoposide: Given IV \> \> G-CSF

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I	54
Arm II	54

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I	54	Not reported	Not reported	Not reported	Not reported
Arm II	53	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
54
group Id
OG001
value
53

denoms

counts
group Id
OG000
value
54
group Id
OG001
value
54
units
Participants

description

Number of patients reporting at least one adverse event at least possibly related to treatment.

groups

description
Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant. \> \> carmustine: Given IV \> \> thiotepa: Given IV \> \> stem cell transplant \> \> G-CSF
id
OG000
title
Arm I
description
Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy. \> \> cytarabine: Given IV \> \> etoposide: Given IV \> \> G-CSF
id
OG001
title
Arm II

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

7 years

title

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice